Pharmaceutical Peptides

Tirzepatide

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This 39-amino acid synthetic peptide features a C-20 fatty diacid moiety for albumin binding. It has demonstrated unprecedented efficacy in type 2 diabetes and obesity clinical trials, representing a paradigm shift in incretin-based therapy.

Technical Specifications

Sequence / Structure39-amino acid peptide based on GIP with GLP-1 receptor activity
Molecular Weight4813.45 g/mol
Purity≥97%
AppearanceWhite lyophilized powder
StorageStore at -20°C, reconstituted at 2-8°C
SolubilitySoluble in water at pH 4-5

Application Areas

  • Dual incretin receptor research
  • Type 2 diabetes studies
  • Obesity research
  • Metabolic syndrome investigation
  • Beta-cell preservation studies
  • Cardiovascular metabolic research

Published Research on Tirzepatide

Frias JP, Davies MJ, Rosenstock J, et al. (2021) — Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. DOI: 10.1056/NEJMoa2107519

Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022) — Tirzepatide once weekly for the treatment of obesity. N Engl J Med. DOI: 10.1056/NEJMoa2206038

Coskun T, Sloop KW, Loghin C, et al. (2018) — LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. DOI: 10.1016/j.molmet.2018.06.004

Frequently Asked Questions About Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist peptide that simultaneously activates both incretin hormone receptors for enhanced metabolic effects.

Dual GIP/GLP-1 activation provides complementary mechanisms: GLP-1 receptor activation reduces appetite and improves glucose control, while GIP receptor activation enhances fat metabolism and insulin sensitivity.

Our wholesale Tirzepatide is ≥97% pure with comprehensive analytical certificates including HPLC and mass spectrometry data.

Store lyophilized Tirzepatide at -20°C. Reconstituted solutions should be refrigerated at 2-8°C and used promptly.

While Semaglutide is a pure GLP-1 agonist, Tirzepatide additionally activates GIP receptors, showing superior weight loss and glycemic control in head-to-head trials.

We offer various quantity tiers with progressive volume discounts. Contact us for customized wholesale pricing.

Related Pharmaceutical Peptides

Request Price List